Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP

CONCLUSIONS: Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior sinonasal surgery.PMID:33847325 | DOI:10.4193/Rhin20.415

Source: Rhinology - April 13, 2021 Category: ENT & OMF Authors: M Desrosiers L P Mannent N Amin G W Canonica P W Hellings P Gevaert J Mullol S E Lee S Fujieda J K Han C Hopkins W Fokkens R Jankowski S H Cho X Mao M Zhang M S Rice A H Khan S Kamat N Patel N M H Graham M Ruddy C Bachert Source Type: research